Annuncio • Mar 07
Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026 Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South Korea New Risk • Nov 21
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.4b market cap, or US$35.6m). New Risk • Nov 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩32.7b market cap, or US$22.6m). Annuncio • Nov 03
Precision Biosensor, Inc. announced that it has received KRW 17.00000112 billion in funding from Kwang Dong Pharmaceutical Co., Ltd. On November 3, 2025, Precision Biosensor, Inc announced that it has raised KRW 17,000,001,120 in funding and closed the transaction. New Risk • Jun 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩1.8b free cash flow). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩40.8b market cap, or US$29.6m). Reported Earnings • Mar 25
Full year 2024 earnings released: ₩629 loss per share (vs ₩387 loss in FY 2023) Full year 2024 results: ₩629 loss per share (further deteriorated from ₩387 loss in FY 2023). Revenue: ₩19.1b (down 6.2% from FY 2023). Net loss: ₩7.31b (loss widened 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings. Annuncio • Mar 06
Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025 Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South Korea New Risk • May 25
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩7.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.6b free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩49.4b market cap, or US$36.2m). Reported Earnings • Mar 22
Full year 2023 earnings released: ₩387 loss per share (vs ₩590 loss in FY 2022) Full year 2023 results: ₩387 loss per share (improved from ₩590 loss in FY 2022). Revenue: ₩20.4b (flat on FY 2022). Net loss: ₩4.49b (loss narrowed 34% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings. Annuncio • Feb 07
Precision Biosensor, Inc. announced that it expects to receive KRW 3 billion in funding from Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd. and another investor Precision Biosensor, Inc. announced a private placement to issue Series 3 Bearer Interest Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 3,000,000,000 on February 6, 2024. The transaction will include participation from new investors Shinhan Investment & Securities Co., Ltd. for KRW 1,000,000,000, Korea Investment & Securities Co., Ltd. (In the fiduciary position of Fund 1) for KRW 500,000,000 and JB Mezzanine New Technology Business Investment No. 2 for KRW 1,500,000,000. The bonds bear zero coupon rate and 3% maturity rate and matures on February 9, 2029. The transaction has been approved by the shareholders of the company and is expected to close on February 8, 2024. The bonds are 100% convertible into 596,658 shares at a fixed conversion price of KRW 5,028 from February 8, 2025 to January 8, 2029. Reported Earnings • Mar 18
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: ₩368 loss per share (up from ₩550 loss in FY 2020). Revenue: ₩15.9b (up 83% from FY 2020). Net loss: ₩4.15b (loss narrowed 16% from FY 2020). Revenue was in line with analyst estimates. Reported Earnings • Nov 17
Third quarter 2021 earnings released: ₩58.00 loss per share (vs ₩36.63 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩4.67b (down 8.1% from 3Q 2020). Net loss: ₩655.8m (down 280% from profit in 3Q 2020).